1,721,136 research outputs found
Protein kinase CK2 as a druggable target
No full textCK2 is probably the most pleiotropic Ser/Thr protein kinase with hundreds of endogenous substrates already known, which are implicated in a variety of cellular functions. At variance with most protein kinases whose activity is turned on only in response to specific stimuli, and whose genetic alterations often underlie pathological situations, CK2 is not susceptible to tight regulation and there are no mutations known to affect its constitutive activity. Nevertheless an abnormally high level of CK2 is invariably found in tumours, and solid arguments have accumulated suggesting that CK2 plays a global pro-survival function, which under special circumstances creates a cellular environment particularly favourable to the development and potentiation of the tumour phenotype. Therefore any strategy aimed at attenuating CK2 activity may represent a "master key" for the treatment of different neoplastic diseases. Waiting for the clarification of the epigenetic mechanisms promoting the rise of CK2 in cells predisposed to develop a tumour phenotype, a useful pharmacological aid can come from the improvement of a number of fairly potent and selective CK2 inhibitors already available
Inhibitors of protein kinase CK2: structural aspects
No full textProtein kinase CK2 is one of the most challenging members of the kinase superfamily. Although this protein has been the subject of intensive studies over the last 50 years, very little is known about its precise biological function and mode of regulation. The CK2 holoenzyme is composed of two catalytic α- and two regulatory β-subunits and is classified as an acidophilic Ser/Thr kinase. Unique properties of the catalytic α-subunit are its intrinsic activity and high pleiotropicity. CK2 is supposed to be involved in many fundamental aspects of the normal cell life as well as in degenerative processes that can lead to cancer or tumor pathologies. This makes CK2 an interesting target for the development of inhibitors with pharmacological perspectives. The inhibitors studied are directed to the CK2 ATP-binding site that, among the known kinases, carries some distinctive features as indicated by its ability to use both ATP and GTP as co-substrates and the low susceptiveness to staurosporine inhibition. On the basis of three-dimensional crystal structures, we describe and discuss the effects of the binding to CK2 of inhibitors with a potency in the low micromolar range belonging to different chemical families, i.e., benzotriazoles, anthraquinones, and quinazolinones. The overall structure of the protein is poorly affected by the binding of these small molecules. In the proximity of the binding site, the most affected residues are Asn118, His160, Met163, and those of the glycine-rich loop. Two of the inhibitors, namely tetrabromo-2-benzotriazolo (TBB) and the indoloquinazolinone IQA, display a significant selectivity among panels of tens of different kinases. An important common energetic contribution to the inhibitors' binding is ascribed to the hydrophobic interaction with the apolar surface region of the CK2 binding cleft. The shape and the reduced dimension of the CK2 active site in comparison with other kinases are essential in explaining the selectivity of these inhibitors as well as the anomalous low potency of staurosporine
Protein kinase CK2 mutants defective in substrate recognition - Purification and kinetic analysis
No full textFive mutants of protein kinase CK2 alpha subunit in which altogether 14 basic residues were singly to quadruply replaced by alanines (K74A,K75A,K76A,K77A; K79A, R80A,K83A; R191A,R195A,K198A; R228A; and R278A, K279A,R280A) have been purified to near homogeneity either as such or after addition of the recombinant beta subunit. By this latter procedure five mutated tetrameric holoenzymes were obtained as judged from their subunit composition, sedimentation coefficient on sucrose gradient ultracentrifugation, and increased activity toward a specific peptide substrate as compared with the isolated alpha subunits. The kinetic constants and the phosphorylation efficiencies (V(max)/Km) of all the mutants with the parent peptide RRRADDSDDDDD and a series of derivatives, in which individual aspartic acids were replaced by alanines, have been determined. Three mutants, namely K74A,K75A,K76A,K77A; K79A, R80A,K83A; and R191A,R195A, K198A, display dramatically lower phosphorylation efficiency and 8-50-fold higher Km values with the parent peptide, symptomatic of reduced attitude to bind the peptide substrate as compared with CK2 wild type. Such differences either disappear or are attentuated if the mutants R191A,R195A, K198A; K79A,R80A,K83A; and K74A,K75A, K76A,K77A are assayed with the peptides RRRADDSADDDD, RRRADDSDDADD, and RRRADDSDDDAA, respectively. In contrast, the phosphorylation efficiencies of the other substituted peptides decrease more markedly with these mutants than with CK2 wild type. These data show that one or more of the basic residues clustered in the 191-198, 79-83, and 74-77 sequences are implicated in the recognition of the acidic determinants at positions +1, +3, and +4/+5, respectively, and that if these residues are mutated, the relevance of the other acidic residues surrounding serine is increased. In contrast the other two mutants, namely R228A and R278A,K279A, R280A, display with all the peptides V(max) values higher than CK2 wild type, counterbalanced however by somewhat higher Km values. It can be concluded from these data that all five mutations performed are compatible with the reconstitution of tetrameric holoenzyme, but all of them influence the enzymatic efficiency of CK2 to different extents. Although the basic residues mutated in the 74-77, 79-83, and 191-198 sequences are clearly implicated in substrate recognition by interacting with acidic determinants at variable positions downstream from serine, the other basic residues seem to play a more elusive and/or indirect role in catalysis
The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation
Full text linkMany polyphenolic compounds have been reported to inhibit protein kinases, with special reference to CK2, a pleiotropic serine/threonine kinase, implicated in neoplasia, neurodegenerative disease, and viral infections. In general however these compounds are not endowed with stringent selectivity. Among them quinalizarin (1,2,5,8-tetrahydroxyanthraquinone) turned out to be particularly potent (Ki = 0.058 μM) and quite selective as judged by profiling it on a small panel of 70 protein kinases. Here, by profiling quinalizarin on a larger panel of 140 kinases we reach the conclusion that quinalizarin is one of the most selective inhibitors of CK2, superior to the first-in-class CK2 inhibitor, CX-4945, now in clinical trials for the treatment of cancer. Moreover here we show that quinalizarin is able to discriminate between the isolated CK2 catalytic subunit (CK2α) and CK2 holoenzyme (CK2α2 β2), consistent with in silico and in vitro analyses
POLYAMINES AS NEGATIVE REGULATORS OF CASEIN KINASE-2 - THE PHOSPHORYLATION OF CALMODULIN TRIGGERED BY POLYLYSINE AND BY THE ALPHA[66-86] PEPTIDE IS PREVENTED BY SPERMINE
No full textCalmodulin and other protein substrates of casein kinase-2 (CK2) are not phosphorylated by CK2 holoenzyme under basal conditions. The non catalytic beta-subunit of CK2 is responsible for such a down-regulation which can be overcome by the addition of polylysine [Meggio, F. et al. (1992) Eur. J. Biochem. 205, 939-945]. Here we show that the peptide CVVKILKPVKKKKIKREIKILE, reproducing the basic insert 66-86 of CK2 catalytic subunit, can mimick polylysine in triggering the latent "calmodulin kinase" activity of CK2 holoenzyme, and that spermine and, to a lesser extent, spermidine, but not putrescine, can reversibly and dose-dependently counteract such an activation. Spermine also abolishes the stimulation by polybasic peptides of basal CK2 activity. These findings disclose the possibility that spermine may act in vivo as a negative regulator of CK2 activity toward a category of substrates, like calmodulin and ornithine decarboxylase, whose phosphorylation is dependent on polybasic peptides
PHOSPHORYLATION OF SYNTHETIC FRAGMENTS OF INHIBITOR-2 OF PROTEIN PHOSPHATASE-1 BY CASEIN KINASE-1 AND KINASE-2 - EVIDENCE THAT PHOSPHORYLATED RESIDUES ARE NOT STRICTLY REQUIRED FOR EFFICIENT TARGETING BY CASEIN KINASE-1
No full textThe major phosphorylation site for both casein kinase-2 (CK2) and casein kinase-1 (CK1) in protein phosphatase-1 (PP-1) inhibitor-2 (I-2) is Ser86. Minor phosphorylation sites affected by either CK2 or CK1 are Ser120/Ser121 and Ser174, respectively. A synthetic peptide of 25 amino acids encompassing residues 67-93 of I-2 is phosphorylated by either CK2 or CK1 at its seryl residue corresponding to Ser86 with higher Vmax and Km values similar to those of the intact protein (9 vs 7.2 microM and 14.2 vs 5.3 microM with CK2 and CK1, respectively). No detectable phosphorylation of this peptide which also includes the glycogen synthase kinase-3 (GSK-3) site (Thr72), could be observed with either GSK-3 or p34cdc2 kinase whether or not its seryl residue equivalent to Ser86 had been previously phosphorylated by CK2. Shorter derivatives of I-2(67-93), encompassing residues 72-93 and 78-93, are also readily phosphorylated by both CK1 and CK2, with phosphorylation efficiencies similar to those of the parent peptide. A synthetic heptadecapeptide reproducing the phosphoacceptor site around Ser120/Ser121 is phosphorylated by CK2, but not to any detectable extent by CK1, with a Km value fivefold higher than that of the corresponding pentadecapeptide including Ser86 (78-93). A synthetic pentadecapeptide (166-180) reproducing the phosphoacceptor site around Ser174 is phosphorylated by CK1 less efficiently than the pentadecapeptide including its main phosphorylation site (78-93) (Km 280 microM vs 33 microM). This peptide is readily phosphorylated by CK2 as well, although it lacks the canonical consensus sequence for CK2 and its Ser174 is almost unaffected by CK2 in intact I-2. These data provide the clear-cut demonstration that the consensus sequence with N-terminal prephosphorylated residue(s), SerP/ThrP-Xaa-Xaa-Ser/Thr, [Flotow, H., Graves, P. R., Wang, A., Fiol, C. J., Roeske, R. W. & Roach, P. J. (1990) J. Biol. Chem. 265, 14264-14269; Meggio, F., Perich, J. W., Reynolds, E. C. & Pinna, L. A. (1991) FEBS Lett. 283, 303-306] is not always required to achieve efficient and high-affinity phosphorylation by CK1. They also show that the specificity determinants for I-2 phosphorylation by either CK2 or CK1, but not by GSK3, are entirely grounded on local structural features of the phosphoacceptor site, being only marginally affected by the overall structure of I-2
Regulation of casein kinase-2 (CK2) by polyamines and other polycationic effectors" in Polyamines: Biological and Clinical Aspects
No full textFeatures and potentials of ATP-site directed CK2 inhibitors
No full textA panel of quite specific, fairly potent and cell-permeable inhibitors of protein kinase CK2 belonging to the classes of condensed polyphenolic compounds, tetrabromobenzimidazole/triazole derivatives and indoloquinazolines have been developed, with K-i values in the submicromolar range. Nine structures have been solved to date of complexes between the catalytic a subunit of CK2 and a number of these compounds, many of which display a remarkable specificity toward CK2 as compared to a panel of > 30 kinases tested. The structural basis for such selectivity appears to reside in the shape and size of a hydrophobic pocket adjacent to the ATP binding site where these ATP competitive ligands are entrapped mainly by van der Waals interactions and by an energy contribution derived from the hydrophobic effect. In CK2, this cavity is smaller than in the majority of other protein kinases due to a number of unique bulky apolar residues. Consequently, the replacement of two of these residues (V66 and 1174) in human CK2 alpha with alanines gives rise to mutants, which are markedly less susceptible than wild type to these classes of inhibitors. Cell-permeable CK2 inhibitors have been successfully employed, either alone or in combination with CK2 mutants refractory to inhibition, to dissect signalling pathways affected by CK2 and/or to validate the identification of in vivo targets of this pleiotropic kinase. Moreover, the remarkable pro-apoptotic efficacy of these compounds toward cell lines derived from a wide spectrum of tumors, disclose the possibility that in perspective CK2 inhibitors might become leads for the development of anti-cancer drugs. (c) 2005 Elsevier B.V. All rights reserved
Generation of mutants of CK2 alpha which are dependent on the beta-subunit for catalytic activity.
No full textTo shed light on the structural features underlying high constitutive activity of protein kinase CK2 a number of mutants of the human CK2alpha-subunit altered in the interactions between the N-terminal segment and the activation loop have been generated and shown to be defective in catalytic activity. In particular the truncated mutant delta2-12 displays under standard conditions an almost complete loss of catalytic activity accounted for by a dramatic rise in its Km forATP (from 10 to 206 microM) and a reduced Kcat. Such a drop in efficiency is paralleled by conformational disorganization, as judged from Superdex 75 gel filtration profile. Both catalytic properties and gel filtration behaviour similar to those of wild type CK2alpha were restored upon association with the regulatory beta-subunit, suggesting that constitutive activity is conferred to CK2alpha and to CK2 holoenzyme through different molecular mechanisms. In the holoenzyme an assumable release of tension at the backbone of Ala-193 (as seems to be indicated by a comparison of the crystal structures of maize CK2alpha alone vs. a CK2alpha-beta peptide complex) may result in the ability of the activation loop to adopt its proper conformation independently of interactions with the N-terminal segment
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance
Full text linkProtein kinase CK2 inhibition has long been considered as an attractive anti-cancer strategy based on the following considerations: CK2 is a pro-survival kinase, it is frequently over-expressed in human tumours and its over-expression correlates with a worse prognosis. Preclinical evidence strongly supports the feasibility of this target and, although dozens of CK2 inhibitors have been described in the literature so far, CX-4945 (silmitasertib) was the first that entered into clinical trials for the treatment of both human haematological and solid tumours. However, kinase inhibitor monotherapies turned out to be effective only in a limited number of malignancies, probably due to the multifaceted causes that underlie them, supporting the emerging view that multi-targeted approaches to treat human tumours could be more effective
- …
